RMD

ResMed (RMD), a medical products company specializing in respiratory disorders, has demonstrated a consistent track record of beating earnings estimates with an average surprise of 2.12% over the past two quarters. The company's positive Earnings ESP (+0.11%) combined with its Zacks Rank #3 (Hold) rating suggests another potential earnings beat is likely in its next quarterly report expected on October 29, 2026.

ResMed is set to report Q1 fiscal 2027 results on October 29, with revenues projected at $1.39 billion (up 4%) and EPS expected to rise 4.7% to $2.67. The Sleep and Breathing Health segment is anticipated to grow 6.4% driven by device demand and new product launches, while Residential Care Software revenues are expected to decline 12.7% following the September 2026 sale of MatrixCare to Frazier Healthcare Partners. The company has a Zacks Rank #3 with a negative Earnings ESP of -0.60%.

ResMed is expected to report Q3 2026 earnings of $2.67 per share (up 4.7% YoY) with revenues of $1.39 billion (up 4% YoY) on October 29. However, the company's Earnings ESP is -0.60%, indicating recent analyst pessimism, combined with a Zacks Rank #3, making it difficult to predict an earnings beat. Despite a strong historical track record of beating estimates, ResMed does not appear to be a compelling earnings-beat candidate.

The global digital health and remote patient monitoring market is projected to grow from $26.8 billion in 2025 to $80.8 billion by 2031, expanding at a 20.2% CAGR. Growth is driven by rising chronic disease management demand, expanding reimbursement coverage, and maturing wearable sensor technology, enabling a shift from episodic facility-centered care to continuous connected care models.